Alaunos Therapeutics Inc (NAS:TCRT)
$ 1.15 0.07 (6.48%) Market Cap: 18.41 Mil Enterprise Value: 12.35 Mil PE Ratio: 0 PB Ratio: 3.83 GF Score: 38/100

Alaunos Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 17, 2023 / 03:45PM GMT
Release Date Price: $8.26 (-3.44%)
Gil Blum
Needham & Company - Analyst

Hello, everyone. My name is Gil Blum and I am a senior biotech analyst here at Needham & Company. It is my pleasure to have with me today, Kevin Boyle and Drew Deniger from Alaunos Therapeutics management. As a reminder, any viewers who are watching through our conference portal are able to submit questions via the Ask a Question box below the video feed window.

And with that, Kevin, you have the floor.

Kevin Boyle
Alaunos Therapeutics, Inc. - CEO

Good morning and thank you, Gil, to you and to Needham for the invitation to present at the conference today. And to the investors, we appreciate your interest in Alaunos Therapeutics and our TCR-T platform attacking solid tumors. I'm Kevin Boyle, the Chief Executive Officer of Alaunos, and today I will be joined by Drew, our Vice President of Research and Development.

Alaunos is laser-focused on leading the scientific development of T-cell receptor therapies to revolutionize how solid cancer treatment are performed and improve patient outcomes. In the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot